Skip to main content
Equibles
TNDM logo

TNDM · Tandem Diabetes Care Inc

Track TNDM — free

Use TNDM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TNDM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$22.72 -0.41 (-1.77%) At close · Aug 14
Market Cap
$1.58B
Shares
69.58M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$22.72 Open$22.92 Day$22.36–22.92 52W close$10.66–28.26 Avg vol 30d2.0M Short int11.2M · 16.2% float · 6.6d Short vol63% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 6, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +17%
      above
      Price vs 50-day avg +29%
      above
      RSI (14) 69
      neutral
      MACD trend Positive
      52-week position 69%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return +33%
      trailing
      6-month return −20%
      trailing
      YTD return +3%
      this year
      Relative strength −33%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $18 › 200d $19 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +46 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      16.16% of float · ▼ -14.3% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      266 holders — mid 3-yr range
      Squeeze score 80
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth +8%
      Y/Y
      Gross margin 54%
      expanding
      EPS growth −107%
      Y/Y
      Free cash flow $-29.7M
      Balance sheet $260.1M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 78%
      annualized · 1-yr
      Max drawdown −55%
      past year
      ATR 5.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 6, 2026
      Sales · year ending December 31, 2026 $1.07B – $1.09B
      U.S. sales · year ending December 31, 2026 $730M – $745M
      Adjusted EBITDA margin · year ending December 31, 2026 Non-GAAP 5% – 6%
      Gross margin · year ending December 31, 2026 56% – 57%
      International sales · year ending December 31, 2026 $335M – $340M
      Non-cash charges included in cost of goods sold and operating ex · year ending December 31, 2026 $85M
      Non-cash, stock-based compensation expense · year ending December 31, 2026 $65M
      Depreciation and amortization expense · year ending December 31, 2026 $20M
      Prior guidance period ended · from the 8-K filed Nov 6, 2025
      Sales for the full year · year ending December 31, 2025 $1B
      Gross margin · full year 53% – 54%
      Sales in the United States · year ending December 31, 2025 $700M
      Non-cash charges included in cost of goods sold and operating ex · full year $115M
      Non-cash, stock-based compensation expense · full year $95M
      Depreciation and amortization expense · full year $20M
      Guided vs delivered · last 1 settled
      Sales for the full year year ending December 31, 2025
      guided $1B
      $1.01B Beat +1.5%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +17% Bullish
      Price vs 50-day avg
      +29% Bullish
      RSI (14)
      69 Neutral
      MACD trend
      Positive Bullish
      52-week position
      69% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $18 › 200d $19 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +46 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      16.16% of float · ▼ -14.3% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      266 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $11 Now $23 · 69% Range high $28
      vs 200-day avg +17% vs 50-day avg +29%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA margin non-GAAP 2% Six Months Ended June 30, 2026 —
      Non-GAAP free cash flow non-GAAP -33.89M Six Months Ended June 30, 2026 —
      Non-GAAP net loss non-GAAP -41.56M Six Months Ended June 30, 2026 —
      Non-GAAP operating loss non-GAAP -31.23M Six Months Ended June 30, 2026 —
      Non-GAAP operating margin non-GAAP -6% Six Months Ended June 30, 2026 —
      Pump shipments 33,000 Q2 2026 —
      Pump shipments in the U.S. 22,000 Q2 2026 —
      Free cash flow non-GAAP $3.1M Fourth Quarter 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TNDM
      Tandem Diabetes Care Inc
      this stock
      		$1.58B +3.4% +7.9% — 16.2%
      ABT
      Abbott Laboratories
      		 $193.78B -11.2% +5.7% 31.2 1.3%
      SYK
      Stryker Corp
      		 $130.11B -3.5% +11.2% 35.2 2.2%
      MDT
      Medtronic plc
      		 $116.83B -5.0% +8.4% 24.5 1.4%
      BSX
      Boston Scientific Corp
      		 $75.11B -45.6% +12.5% 21.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      266
      % held
      121.7%
      Net QoQ
      +184.3K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      242
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      11.2M
      Days to cover
      6.6d
      Change
      -1.9M sh
      View
      Short Volume
      Short vol %
      63%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      33.8K
      Value
      $521.0K
      As of
      Jul 7, 2026
      View
      Off-Exchange
      Off-exchange %
      38.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      Mar 3, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $1.0B
      Net income (FY)
      $-204.7M
      EPS diluted
      $-3.04
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 11, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $6.0K
      Shares
      361
      Filed
      Jun 17, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TNDM +1.5% +33.0% -19.6% +16.5% +3.4%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +1.1% +28.6% -33.4% +12.6% -10.5%
      Key facts CIK 1438133 CUSIP 875372203 13F (30d) 249 filings 247 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)